查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602796

肥胖藥物市場：依治療類型、最終用途分類 - 2025-2030 年全球預測

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肥胖藥物市場規模為99.8億美元，預計2024年將達108.1億美元，複合年成長率為8.44%，2030年將達176億美元。

肥胖藥物市場涵蓋治療肥胖及相關疾病的藥物和治療方法的開拓、生產和銷售。該行業的定義是，日益成長的對抗全球肥胖流行病的需求是由肥胖率上升以及糖尿病、心血管疾病和某些癌症等相關健康併發症引起的。人們對肥胖對健康影響的認知不斷提高、醫療保健成本增加以及針對體重管理的公共衛生努力推動了對肥胖藥物的需求。其應用包括藥品、營養食品和生活方式干涉，最終用戶範圍從醫療保健提供者和健身中心到尋求減重解決方案的個人消費者。影響該市場的主要成長要素包括藥物開發的技術進步、政府對醫療保健創新的獎勵以及不斷增加的研發投資。此外，生物技術的進步和消費者對體重管理藥物干預措施的接受程度不斷提高也推動了市場的發展。

主要市場統計
基準年[2023] 99.8億美元
預測年份 [2024] 108.1億美元
預測年份 [2030] 176億美元
複合年成長率（%） 8.44%

全球肥胖症盛行率不斷上升，以及對更有效、更安全的治療方法日益成長的需求，創造了潛在的商機。公司可以透過開發針對特定基因譜的新型療法和個人化醫療方法來利用這些機會。然而，它們面臨著嚴格的監管要求、高昂的研發成本以及與抗肥胖藥物相關的潛在副作用等限制和挑戰，阻礙了它們的更廣泛採用。創新領域包括探索具有體重管理作用的天然成分、研究腸道微生物組在肥胖中的作用，以及推廣聯合治療以提高療效並減少副作用。隨著市場的發展，公司擴展到正在經歷人口和生活方式變化而導致肥胖率增加的新興市場是有利的。在這種競爭格局中，與研究機構和醫療保健提供者的合作和夥伴關係對於克服挑戰和促進創新至關重要。了解市場趨勢和消費行為使公司能夠有效地駕馭這個動態空間。

市場動態：揭示快速發展的肥胖藥物市場的關鍵市場洞察

供需的動態交互作用正在改變肥胖藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 肥胖及相關疾病增加
    • 由於缺乏運動而導致久坐的生活方式增加
    • 新型抗肥胖藥物介紹
  • 市場限制因素
    • 肥胖藥物副作用的風險，包括精神疾病和中風
  • 市場機會
    • 正在進行的臨床試驗和研發活動
    • 與臨床顯著體重減輕相關的藥物標靶增加
  • 市場挑戰
    • 缺乏體重管理知識

波特的五力：駕馭肥胖藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肥胖藥物市場的外部影響

外部宏觀環境因素在塑造肥胖藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肥胖治療藥物市場的競爭狀況

對肥胖藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 減重藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估減重藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃肥胖藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對肥胖藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肥胖及相關疾病的發生率增加
      • 由於缺乏運動而導致久坐的生活方式增加
      • 新型抗肥胖藥物介紹
    • 抑制因素
      • 肥胖藥物副作用的風險，例如精神障礙和中風
    • 機會
      • 正在進行的臨床試驗和研發活動
      • 與臨床顯著體重減輕相關的藥物標靶增加
    • 任務
      • 體重管理知識有限
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的肥胖治療藥物市場

  • 藥品
    • 安非他酮-納曲酮
    • Liraglutide
    • 奧利司他
    • 芬特明-托吡酯
    • Semaglutide
  • 治療
    • 可調式胃束帶
    • 內視鏡袖狀胃成形術
    • 胃繞道手術

第7章肥胖藥物市場：依最終用途

  • 門診手術中心
  • 醫院
  • 專科診所

第8章北美和南美肥胖藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區肥胖藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲肥胖藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Norgine BV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus LLC
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market was valued at USD 9.98 billion in 2023, expected to reach USD 10.81 billion in 2024, and is projected to grow at a CAGR of 8.44%, to USD 17.60 billion by 2030.

The scope of the anti-obesity therapeutics market involves developing, producing, and marketing drugs and treatments that address obesity and related conditions. This industry is defined by a growing need to combat the global obesity epidemic, driven by rising obesity rates and associated health complications such as diabetes, cardiovascular diseases, and certain cancers. The necessity for anti-obesity therapeutics stems from heightened awareness of obesity's health effects, increased healthcare costs, and public health initiatives targeting weight management. Its application includes pharmaceuticals, dietary supplements, and lifestyle interventions, with end-users ranging from healthcare providers and fitness centers to individual consumers seeking weight loss solutions. Key growth factors influencing this market include technological advancements in drug development, government incentives for healthcare innovation, and increased investment in research and development. Additionally, the market is buoyed by a surge in biotechnology advancements and growing consumer acceptance of pharmaceutical interventions for weight management.

KEY MARKET STATISTICS
Base Year [2023] USD 9.98 billion
Estimated Year [2024] USD 10.81 billion
Forecast Year [2030] USD 17.60 billion
CAGR (%) 8.44%

Potential opportunities arise from the increasing prevalence of obesity worldwide, driving demand for more effective and safer treatments. Companies can capitalize on these opportunities by developing novel therapeutics and personalized medicine approaches tailored to specific genetic profiles. However, the market faces limitations and challenges, such as stringent regulatory requirements, high R&D costs, and potential side effects associated with anti-obesity drugs, which hinder broader adoption. Innovation areas include exploring natural ingredients with weight management benefits, investigating the role of gut microbiome in obesity, and advancing combination therapies to enhance efficacy and reduce side effects. As the market evolves, businesses can benefit from expanding into emerging markets experiencing demographic and lifestyle changes driving obesity rates. In this competitive landscape, collaborations and partnerships with research institutions and healthcare providers are crucial to overcoming challenges and fostering innovation. Insights into market trends and consumer behavior will enable companies to navigate this dynamic sector effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Obesity Therapeutics Market

The Anti-Obesity Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of obesity and related disorder
    • Rising adoption of sedentary lifestyle due to lack of exercise
    • Introduction of novel anti-obesity drugs
  • Market Restraints
    • Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
  • Market Opportunities
    • Ongoing clinical trials and research & development activities
    • Increasing number of drug targets associated with clinically significant weight loss
  • Market Challenges
    • Limited of knowledge regarding weight management

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Obesity Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Obesity Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Obesity Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Obesity Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Obesity Therapeutics Market

A detailed market share analysis in the Anti-Obesity Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Obesity Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Obesity Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Obesity Therapeutics Market

A strategic analysis of the Anti-Obesity Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals, Inc., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, and Vivus LLC.

Market Segmentation & Coverage

This research report categorizes the Anti-Obesity Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-naltrexone, Liraglutide, Orlistat, Phentermine-topiramate, and Semaglutide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.
  • Based on End-use, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of obesity and related disorder
      • 5.1.1.2. Rising adoption of sedentary lifestyle due to lack of exercise
      • 5.1.1.3. Introduction of novel anti-obesity drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of side effects of anti-obesity therapeutics such as psychiatric disorder as well as strokes
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing clinical trials and research & development activities
      • 5.1.3.2. Increasing number of drug targets associated with clinically significant weight loss
    • 5.1.4. Challenges
      • 5.1.4.1. Limited of knowledge regarding weight management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Bupropion-naltrexone
    • 6.2.2. Liraglutide
    • 6.2.3. Orlistat
    • 6.2.4. Phentermine-topiramate
    • 6.2.5. Semaglutide
  • 6.3. Treatments
    • 6.3.1. Adjustable Gastric Banding
    • 6.3.2. Endoscopic Sleeve Gastroplasty
    • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by End-use

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Hospitals
  • 7.4. Specialty Clinics

8. Americas Anti-Obesity Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anti-Obesity Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Boehringer Ingelheim International GmbH
  • 2. Bristol-Myers Squibb Company
  • 3. Currax Pharmaceuticals LLC
  • 4. Eisai Co., Ltd.
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co., Inc.
  • 9. Norgine B.V.
  • 10. Novartis AG
  • 11. Novo Nordisk A/S
  • 12. Pfizer Inc.
  • 13. Rhythm Pharmaceuticals, Inc.
  • 14. SHIONOGI & Co., Ltd.
  • 15. Takeda Pharmaceutical Company Limited
  • 16. Vivus LLC

LIST OF FIGURES

  • FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 192. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023